241 related articles for article (PubMed ID: 2173105)
1. Impact of cytomegalovirus infection on organ transplant recipients.
Rubin RH
Rev Infect Dis; 1990; 12 Suppl 7():S754-66. PubMed ID: 2173105
[TBL] [Abstract][Full Text] [Related]
2. [Cytomegalovirus infection in transplant recipients].
Gondo H
Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cytomegalovirus infection in the pediatric renal transplant recipient.
Hibberd PL; Rubin RH
Pediatr Nephrol; 1991 Jan; 5(1):112-7. PubMed ID: 1851031
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection in organ transplant recipients.
Hibberd PL; Snydman DR
Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
[TBL] [Abstract][Full Text] [Related]
5. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
8. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus infections in heart and heart-lung transplant recipients.
Wreghitt T
J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412
[TBL] [Abstract][Full Text] [Related]
10. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in the liver transplant recipient. Epidemiology, pathogenesis, and clinical management.
Rubin RH
Clin Liver Dis; 1997 Aug; 1(2):439-52, x. PubMed ID: 15562577
[TBL] [Abstract][Full Text] [Related]
12. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
13. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation.
Wagner JA; Ross H; Hunt S; Gamberg P; Valantine H; Merigan TC; Stinson EB
Transplantation; 1995 Dec; 60(12):1473-7. PubMed ID: 8545877
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus in transplantation - challenging the status quo.
Fishman JA; Emery V; Freeman R; Pascual M; Rostaing L; Schlitt HJ; Sgarabotto D; Torre-Cisneros J; Uknis ME
Clin Transplant; 2007; 21(2):149-58. PubMed ID: 17425738
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]